08.07.19: Not intended for U.S. and UK Media - Important step towards improved treatment for children with venous thromboembolism

Rivaroxaban demonstrates strong efficacy and safety profile in phase III study in children with thromboembolismPhase III EINSTEIN-Jr. study in children concludes the largest pediatric thromboembolism program delivering results consistent with those in adults / Study shows a low risk of recurrent venous thromboembolism (VTE) in children treated with rivaroxaban compared with standard of care with low rates of bleeding / First phase III data on the use of a non-vitamin K oral anticoagulant (NOAC) in a large pediatric population / Study investigated a body weight-adjusted oral 20 mg equivalent dose of rivaroxaban for the prevention of recurrent VTE in children from birth to 17 years of age with confirmed VTE, including cerebral vein and sinus thrombosismehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news